Jun Wang

Citado por

	Total	Desde 2020
Citas	8971	6108
Índice h	53	37
Índice i10	113	100

1400

700

350

1050

200720082009201020112012201320142015201620172018201920202021202220232024202563 69 61 124 187 180 290 285 282 332 340 303 303 606 1167 1357 1399 1385 180

Acceso público

Ver todo

109 artículos

1 artículo

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Chunlong MaResearch specialistDirección de correo verificada de pharmacy.arizona.edu
William DeGradoUCSFDirección de correo verificada de UCSF.edu
Robert LambNorthwestern UniversityDirección de correo verificada de northwestern.edu
Mei HongProfessor of Chemistry, Massachusetts Institute of TechnologyDirección de correo verificada de mit.edu
Yibing WuUniversity of California San FranciscoDirección de correo verificada de ucsf.edu
Michael L KleinTemple UniversityDirección de correo verificada de temple.edu
Giacomo FiorinStaff scientist, National Institutes of HealthDirección de correo verificada de nih.gov
Shao YaoProfessor of Chemistry, National University of SingaporeDirección de correo verificada de nus.edu.sg
Mahesh UttamchandaniAssistant Professor, Departments of Chemistry and Biological Sciences, NUSDirección de correo verificada de dso.org.sg
Hyunil JoUniversity of Pennsylvania, Seoul National University, University of California, San FranciscoDirección de correo verificada de ucsf.edu
Sarah D. CadyChemical Instrumentation Facility, Iowa State UniversityDirección de correo verificada de iastate.edu
Vincenzo CarnevaleiGEM & ICMS - Temple UniversityDirección de correo verificada de temple.edu
Klaus Schmidt-RohrProfessor of Chemistry, Brandeis UniversityDirección de correo verificada de brandeis.edu
Hongyan SunProfessor, Department of Chemistry, City University of Hong KongDirección de correo verificada de cityu.edu.hk
Fang LiThe University of arizonaDirección de correo verificada de email.arizona.edu
Eleonora GiantiThe City University of New York, CUNY, Queens CollegeDirección de correo verificada de qc.cuny.edu
Tuo WangCarl H. Brubaker, Jr., Associate Professor, Michigan State UniversityDirección de correo verificada de msu.edu
Fanghao HuTsinghua UniversityDirección de correo verificada de tsinghua.edu.cn
Abhijit MishraProfessor, IIT GandhinagarDirección de correo verificada de iitgn.ac.in
Gerard C. L. WongUCLA BioE Dept, Chem & Biochem Dept., Microbiology, Immunology, & Mol Genetics Dept, CNSIDirección de correo verificada de seas.ucla.edu

Seguir

Jun Wang

Professor, Rutgers, the State University of New Jersey

Dirección de correo verificada de pharmacy.rutgers.edu - Página principal

Drug discovery Antivirals Influenza Enterovirus Coronavirus


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease C Ma, MD Sacco, B Hurst, JA Townsend, Y Hu, T Szeto, X Zhang, ... Cell research 30 (8), 678-692, 2020	828	2020
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers SD Cady, K Schmidt-Rohr, J Wang, CS Soto, WF DeGrado, M Hong Nature 463 (7281), 689-692, 2010	732	2010
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M^pro and cathepsin L MD Sacco, C Ma, P Lagarias, A Gao, JA Townsend, X Meng, P Dube, ... Science Advances 6 (50), eabe0751, 2020	378	2020
Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus J Wang, Y Wu, C Ma, G Fiorin, J Wang, LH Pinto, RA Lamb, ML Klein, ... Proceedings of the National Academy of Sciences 110 (4), 1315-1320, 2013	265	2013
Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors C Ma, Y Hu, JA Townsend, PI Lagarias, MT Marty, A Kolocouris, J Wang ACS pharmacology & translational science 3 (6), 1265-1277, 2020	249	2020
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... Nature communications 12 (1), 6055, 2021	245	2021
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir Y Hu, EM Lewandowski, H Tan, X Zhang, RT Morgan, X Zhang, ... ACS Central Science 9 (8), 1658-1669, 2023	221	2023
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor Y Hu, X Meng, F Zhang, Y Xiang, J Wang Emerging microbes & infections 10 (1), 317-330, 2021	183	2021
Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2 J Wang, C Ma, G Fiorin, V Carnevale, T Wang, F Hu, RA Lamb, LH Pinto, ... Journal of the American Chemical Society 133 (32), 12834-12841, 2011	171	2011
Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay C Ma, MD Sacco, Z Xia, G Lambrinidis, JA Townsend, Y Hu, X Meng, ... ACS central science 7 (7), 1245-1260, 2021	167	2021
Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission NW Schmidt, A Mishra, J Wang, WF DeGrado, GCL Wong Journal of the American Chemical Society 135 (37), 13710-13719, 2013	160	2013
Protein and small molecule microarrays: powerful tools for high-throughput proteomics M Uttamchandani, J Wang, SQ Yao Molecular Biosystems 2 (1), 58-68, 2006	157	2006
Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus J Wang, JX Qiu, C Soto, WF DeGrado Current opinion in structural biology 21 (1), 68-80, 2011	148	2011
Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors N Kitamura, MD Sacco, C Ma, Y Hu, JA Townsend, X Meng, F Zhang, ... Journal of medicinal chemistry 65 (4), 2848-2865, 2021	142	2021
Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine … SD Cady, J Wang, Y Wu, WF DeGrado, M Hong Journal of the American Chemical Society 133 (12), 4274-4284, 2011	130	2011
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus V Balannik, J Wang, Y Ohigashi, X Jing, E Magavern, RA Lamb, ... Biochemistry 48 (50), 11872-11882, 2009	127	2009
Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity C Ma, Z Xia, MD Sacco, Y Hu, JA Townsend, X Meng, J Choza, H Tan, ... Journal of the American Chemical Society 143 (49), 20697-20709, 2021	123	2021
Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... BioRxiv, 2020.09. 12.293498, 2020	123	2020
Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus J Wang, C Ma, J Wang, H Jo, B Canturk, G Fiorin, LH Pinto, RA Lamb, ... Journal of medicinal chemistry 56 (7), 2804-2812, 2013	121	2013
Progress and challenges in targeting the SARS-CoV-2 papain-like protease H Tan, Y Hu, P Jadhav, B Tan, J Wang Journal of medicinal chemistry 65 (11), 7561-7580, 2022	119	2022

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores